Payers across the globe are becoming increasingly assertive regarding products whose costs aren’t in line with perceived performance—a trend that shows no signs of slowing down. Financial and performance-based RSAs (PBRSAs) have been widely employed throughout Europe to reduce drug expenditures. While these agreements may not be universally applicable or without challenge, they are gaining momentum in certain markets where they will likely play a role in enhancing economic efficiency.

In their recently published article, Risk-Sharing Agreements in the EU and Considerations for Moving Forward, authors Mike Kuchenreuther and Michael Abrams look at key factors driving risk-sharing agreements that have been implemented to reduce drug expenditures across Europe.